SCHEMBL13769487

SCHEMBL13769487

CC1(C)CN(Cc2ccccc2)C[C@H]1CF

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.47
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
TSHR P16473 1/20 0.44
SIGMAR1 Q99720 1/20 0.43
FUCA1 P04066 2/20 0.42
ACHE P22303 1/20 0.42
NR1I2 O75469 1/20 0.42
RORC P51449 1/20 0.42
ARG1 P05089 1/20 0.41
ARG2 P78540 1/20 0.41
MC4R P32245 1/20 0.41
CYP2D6 P10635 1/20 0.40
LMNA P02545 1/20 0.40
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12167434 0.86 GAA (0.49) GAAMEN1KMT2ATSHRSIGMAR1
SCHEMBL27546199 0.84 GAA (0.47) GAAMEN1KMT2ATSHRSIGMAR1
SCHEMBL12167484 0.84 GAA (0.44) GAAMEN1KMT2ATSHRSIGMAR1
SCHEMBL7508610 0.82 ARG1 (0.45) GAAMEN1KMT2ATSHRSIGMAR1
SCHEMBL4186191 0.81 ARG1 (0.48) GAAMEN1KMT2ATSHRSIGMAR1
SCHEMBL4186190 0.81 ARG1 (0.48) GAAMEN1KMT2ATSHRSIGMAR1
SCHEMBL24773136 0.80 GAA (0.43) GAAMEN1KMT2ATSHRSIGMAR1
SCHEMBL9939340 0.79 GAA (0.51) GAAMEN1KMT2ATSHRSIGMAR1
SCHEMBL10306175 0.79 GAA (0.51) GAAMEN1KMT2ATSHRSIGMAR1
SCHEMBL6197152 0.78 FUCA1 (0.53) GAAMEN1KMT2ATSHRSIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7563805-B2 7-[3-Amino-3,4-dimethylpyrrolidine-1-yl]-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-1,4-dihydro-8-methyl-4-oxoquinoline-3-carboxylic acid: quinoline bactericide; broad spectrum, strong antibacterial activity for Grampositive/-negative including multiple resistant cocci; side effect reductcion; drug design DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-07-21 US disclosed